Skip to main content

Show 12 results Show all

Launching the family planning data toolkit for DMPA-SC self-injection

On September 15, 2021, the PATH-JSI DMPA-SC Access Collaborative hosted this virtual launch and walk-through of the redesigned DMPA-SC Country Data Dashboard and new monitoring, learning, and evaluation (MLE) tools.

The AC data dashboard is an interactive tool that presents available data collected during DMPA-SC self-injection (SI) introduction and scale-up. The dashboard visualizes SI uptake, tracks implementation of key policies, and integrates data use practices to support data-driven decision making. Information presented on the dashboard has changed over time to reflect shifting needs of stakeholders. After undergoing a human centered design exercise to better understand information needs surrounding SI introduction and scale-up, the Access Collaborative recently redesigned the DMPA-SC Country data dashboard. This webinar introduced new data available and demonstrated new features on the dashboard.

The webinar also included an overview of the Access Collaborative’s new MLE toolkit developed to help meet the needs of ministries of health and implementing partners. This toolkit features three tools for dynamic decision-making: a data visualization principles guide, an Excel dashboard how-to guide, and a data use and indicators guide. The tools are primers in how to create dynamic and visually compelling SI program data displays (e.g., dashboards, presentations) that facilitate comprehension and use of SI data for family planning program decision-making. While the toolkit was developed with SI in mind, many of the principles could be applied to data visualization needs across family planning programs and methods.

Institutional Author(s): PATH, JSI, Inc.
Publication date: September, 2021

Toolkit for DMPA-SC monitoring, learning, and evaluation

Data has the power to convey the lived experiences of women and adolescents, highlighting the importance and potential of expanding choices to reduce unmet need for contraception. This monitoring, learning, and evaluation (MLE) toolkit features three tools for dynamic decision-making: A data visualization principles guide, an Excel dashboard how-to guide, and a data use and indicators guide. These are primers on how to create dynamic and visually compelling self-injection program data displays (e.g., dashboards, presentations) that facilitate comprehension and use of self-injection data for family planning program decision-making. While the MLE toolkit was developed with self-injection in mind, many of the principles could be applied to data visualization needs across family planning programs and methods.

We want to hear from you! By completing this short survey, you can help us ensure the tools are meeting the needs of key stakeholders during new product introduction and scale-up. Please contact FPoptions@path.org with any questions or request for assistance.

Institutional Author(s): JSI, Inc., PATH
Publication date: July, 2021

Unlocking DMPA-SC data-sharing between private pharmacies and ministries of health

This webinar hosted by the DMPA-SC Access Collaborative Learning and Action Networks (LAN) on July 21, 2021 highlighted important considerations for private pharmacies in data collection and reporting on self-care products such as DMPA-SC self-injection. Presenters shared their experiences and lessons from introducing DMPA-SC self-injection through private delivery channels in their respective countries.

Highlights included:

  • The specific types of self-injection data collected across countries.
  • Best practices for engaging and motivating private sector pharmacies and drug shops to provide data to the public sector.
  • Tools used by pharmacies to collect self-injection data.

This virtual discussion encouraged all stakeholders—program implementers, researchers, government officials, health providers, and civil society members—to consider private sector perspectives on data collection and reporting practices, highlighting the importance of good private sector data to inform government policies and strategies for monitoring, regulating health products, and procurement.

Institutional Author(s): PATH, JSI, Inc., inSupply Health, Pharmaceutical Society of Kenya, Pharmaceutical Society of Zambia
Publication date: July, 2021

Track20 Project

The Track20 Project, implemented by Avenir Health, monitors progress towards achieving the goals of the global FP2020 initiative, adding an additional 120 million modern method users between 2012 and 2020 in the world’s 69 poorest countries. Track20 works directly with governments in participating FP2020 countries to collect, analyze and use data to monitor progress annually in family planning and to actively use data to improve family planning strategies and plans. Track20 activities and efforts are focused on countries that chose to make a commitment to the FP2020 global initiative, referred to as Track20 Focus Countries. The remaining FP2020 countries, referred to as Additional Track20 Countries, will also receive some technical support.

Institutional Author(s): Avenir Health
Publication date: 2021

Tool Web page

Performance Monitoring for Action (PMA): Family Planning

PMA generates frequent, high-quality surveys monitoring key health indicators in nine countries in Africa and Asia. Data is available open-source for research, program planning, and policy-making. PMA family planning briefs provide a snapshot of select indicators through charts, graphs and tables. Key indicators for family planning include unmet need for family planning, modern contraceptive prevalence rate (​mCPR), and family planning access, equity, quality, and choice.

Institutional Author(s): Johns Hopkins Bloomberg School of Public Health
Publication date: 2021

Tool Web page

Key Indicators for Community-based Access to Injectable Contraception Pilot Studies

An indicator is a measure of program performance that is tracked over time. This document presents potential process and outcome indicators organized according to the phase of the community-based access to injectables (CBA2I) pilot along with the related evaluation questions, data sources and measurement tools. The list can be adapted to local contexts and program goals to assess a pilot’s progress toward intended outputs and achievement of goals.

Institutional Author(s): FHI 360
Publication date: July, 2011

Expanding Access to Contraception through Global Collaboration

This progress report summarizes the work of the DMPA-SC Consortium, a group of public, private, and philanthropic entities that coordinate global support for scale up of DMPA-SC as a contraceptive option in FP2020 countries.

Institutional Author(s): DMPA-SC Consortium
Publication date: March, 2021

How to Introduce and Scale Up DMPA-SC: Practical Guidance from PATH Based on Lessons Learned During Pilot Introduction

This document was created to support ministry of health and nongovernmental partners as they develop strategies to introduce and scale up subcutaneous DMPA (DMPA-SC, brand name Sayana® Press) to increase contraceptive options and access. Available in English and French, the publication provides practical guidance based on results, evidence, and learning from the pilot introductions of DMPA-SC in four countries in Africa.

Institutional Author(s): PATH
Publication date: 2020

DMPA-SC country data dashboard

The country dashboard is a visual presentation of key data for a select list of priority countries; it provides a snapshot of the state and stage of DMPA-SC introduction/scale-up, allowing stakeholders to assess progress, identify roadblocks, guide course corrections, and inform decisions.

Institutional Author(s): PATH
Publication date: August, 2020

Rapid Uptake of the Subcutaneous Injectable in Burkina Faso: Evidence From PMA2020 Cross-Sectional Surveys

The subcutaneous (SC) injectable, widely known by its commercial name Sayana Press, has potential to improve access to contraceptive methods. In Burkina Faso, SC-injectables were first piloted in select regions in 2014 and introduced nationally in 2016. PMA2020 is the first national survey to track programmatic progress of SC-injectable introduction at both population and health facility levels in the country across 2 rounds of data collection: March–May 2016 and November 2016–January 2017. Over this 6-month period, SC-injectable availability at public service delivery points increased from 50% to 85%, largely driven by increases in availability among the non-pilot regions. In terms of use, while the modern contraceptive prevalence rate among all women remained constant at about 23%, SC-injectable prevalence nearly doubled from 1.1% to 2.0%, making up approximately 9% of all modern method users in Burkina Faso by late 2016, though the difference was not statistically significant. Increases were comparable between pilot and non-pilot regions. While the difference was not statistically significant, more rural women were using the method compared with their urban counterparts in the pilot regions, an interesting finding considering the opposite pattern is generally true for contraceptive prevalence nationally. In summary, following national scale-up, data show substantially improved availability of SC-injectables at service delivery points and potential for changes in the method mix in Burkina Faso. In order to further improve contraceptive access and choice, scale-up of community-based distribution of SC-injectables should be considered, especially among rural populations with higher unmet need for family planning.

Institutional Author(s): Institut Supérieur des Sciences de la Population, Bill & Melinda Gates Institute for Population and Reproductive Health
Individual Author(s): Georges Guiella, Shani Turke, Hamadou Coulibaly, Scott Radloff, Yoonjoung Choi
Publication date: March, 2018

Journal Article Link to Article